Where does doxepin fit into managing pruritic skin disease in the horse? (2026)
By Dr Gayle Hallowell
MA VetMB CertVA DipACVIM PhD DipACVECC PFHEA FRCVS
July 2026
Persistent pruritus is one of the more frustrating presentations in equine practice. It is more than a cosmetic or management problem. It is a welfare issue, particularly when horses rub extensively, damage the skin barrier, or progress to self-trauma because of ongoing discomfort.
Doxepin has a place as an adjunctive treatment in horses with persistent pruritus, particularly where self-trauma is becoming a significant feature of the case or where corticosteroids are contraindicated or best avoided. Its role is not to replace diagnosis, but to help reduce pruritus, improve comfort and support case stabilisation while the wider diagnostic and management plan continues.
What is doxepin and how does it work?
Doxepin is a tricyclic antidepressant, but in equine dermatology its relevance lies in both its antipruritic pharmacology and its centrally acting effects. It has potent histamine receptor-blocking activity, particularly at H1 receptors, with additional H2 antagonism also described, and it also inhibits serotonin and norepinephrine re-uptake. In practical terms, this means it may be useful not only in reducing pruritus, but also in selected horses where persistent discomfort, agitation and repetitive rubbing are driving self-trauma.
Which pruritic horses are most likely to benefit?
Pruritus is a clinical sign rather than a diagnosis, and horses may present with mane or tail rubbing, broken hairs, excoriation, recurrent urticaria, or seasonal flare-ups. The differential list is often organised around the main hypersensitivity categories: insect bite hypersensitivity, atopy, food allergy, contact allergy and drug allergy, whilst also considering ectoparasitism and secondary infection as important mimics or complicating factors. This is why even apparently straightforward pruritic cases still require a structured diagnostic approach.
Doxepin is most likely to be considered in horses where reducing pruritus is an important treatment goal. That may include the horse with recurrent seasonal disease, the horse with hypersensitivity-type presentations that are only partly controlled, or the horse in which rubbing and excoriation are beginning to compound the severity of the case. In these patients, management of the clinical signs is valuable because it may improve comfort, reduce further skin injury and make the case easier to manage while longer-term measures are put in place.
When should doxepin be considered in self-traumatising cases?
This becomes particularly important in horses that are self-traumatising. In these cases, the immediate clinical priority is not only to identify the underlying cause of pruritus, but also to interrupt the cycle of discomfort, rubbing, and skin injury before lesions become more extensive and secondary complications develop. Doxepin may therefore be particularly useful in the pruritic horse whose self-trauma reflects not only persistent cutaneous discomfort but also an escalating cycle of agitation and repetitive rubbing.
A note of caution is still important. True equine self-mutilation syndrome is discussed in the literature as a distinct neuro-behavioural disorder, and that should not be conflated with self-trauma secondary to dermatological disease. Doxepin may help the pruritic horse in which self-injury has become difficult to control, especially where a centrally acting adjunct is desirable alongside investigation of the underlying cause.
When might doxepin be useful if corticosteroids are contraindicated?
Doxepin should also be considered where corticosteroids are contraindicated. Corticosteroids remain a familiar therapy in allergic skin disease, but doxepin can be discussed as an alternative or adjunctive option in cases where steroid exposure is less desirable and where reducing pruritus, improving comfort and limiting further self-trauma remain immediate clinical priorities.
What diagnostic work-up should come first?
The diagnostic work-up should remain focused and practical. Signalment, lesion distribution, seasonality, housing, insect exposure, parasite control, secondary infection, and the likelihood of hypersensitivity disease should all be considered in the horse with chronic or recurrent pruritus. Intradermal testing and serum allergen testing such as PAX testing may help identify relevant triggers and support decisions around factors that should be eliminated and at the core of immunotherapy.
How should response to treatment be reassessed?
Reassessment is essential. If the horse improves, the next step is to decide whether that response is sufficient and sustainable within the wider management plan. If the response is poor or only partial, the clinician should reconsider the diagnosis, the persistence of the trigger, the contribution of secondary factors, and whether additional or alternative strategies are needed.
Doxepin therefore sits most comfortably as a key tool in the management of the pruritic horse. Used thoughtfully, it may help reduce pruritus, improve comfort, and limit self-trauma in selected cases, particularly when corticosteroids are not the preferred option. It should always be used with a clear diagnostic framework.
